Mycophenolate Mofetil Usage in Therapy of Systemic Connective Tissue Diseases
No Thumbnail Available
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Mikofenolāta mofetils ir zāles, ko lieto kopš 1990. gada. Farmakodinamiski MMF ir
citostatisks līdzeklis, kurš galvenokārt iedarbojas uz inozīna - 5’- monofosfāta dehidrogenāzi,
tādējadi inhibējot limfocītu proliferāciju.
Iepriekš MMF galvenā indikācija bija samazināt akūtas alotransplantāta atgrūšanas
risku. Pēdējā laikā MMF pielietošana ir palielinājusies, ietverot vairāku reimatoīdo
saslimšanu, piemēram, sistēmiskās sklerozes, sistēmiskās sarkanās vilkēdes, iekaisuma
miopātijas un vaskulītus, ārstēšanu. Lai gan mēs redzam, ka reimatologi izmanto MMF
sistēmisku iekaisuma slimību gadījumā, MMF indikācijas saslimšanas nav iekļautas.
Balstoties uz šo informāciju, veikts dotais pētījums, lai novērtētu MMF ietekmi uz
reimatiskām slimībām un apstiprinātu tā lietošanas derīgumu šīm indikācijām.
Dati tika apkopoti par pacientiem stacionētiem PSKUS ar diagnozi M.32 (SLE) un
M.34 (SSc) laika posmā no 01.01.-2021. līdz 31.12.-2021. Mainīgie lielumi ietvēra vecumu,
medicīnisko aprūpi, slimības aktivitātes rādītāju, dzimumu un glikokortikoīdu lietošanu.
Rezultāti liecina par apmierinošu MMF iedarbību pie šīm saslimšānam, kur slimības
aktivitātes rādītāju var saglabāt uzstādīatjos mērķa diapazonos.
Mycophenolate mofetil is a drug that has been in use since the 1990’s. Pharmacodynamically MMF is a cytostatic drug which due to its effect on inosine-5’- monophosphate dehydrogenase mainly inhibits lymphocyte proliferation. Initially the main indication was to reduce risk for acute allograft rejection. Lately the use of MMF has expanded to include treatment of multiple rheumatic diseases such as systemic sclerosis, systemic lupus erythematosus, inflammatory myopathies and vasculitides. Although we see the use of MMF by rheumatologists within systemic inflammatory diseases, indication lists of MMF remains unchanged. Based on this information, following study is made with the purpose to evaluate the effect of MMF in rheumatic diseases and confirm the validity of its use to these indications. Data was gathered on patients based in the PSKUS due to diagnosis M.32 (SLE) and M.34 (SSc) in the time span 1/1-2021 until 31/12-2021. Variables included age, medical treatment, disease activity score, gender, and use of glucocorticoids. The results show a satisfactory effect of MMF within these diagnoses, where disease activity score can be kept within proposed target ranges
Mycophenolate mofetil is a drug that has been in use since the 1990’s. Pharmacodynamically MMF is a cytostatic drug which due to its effect on inosine-5’- monophosphate dehydrogenase mainly inhibits lymphocyte proliferation. Initially the main indication was to reduce risk for acute allograft rejection. Lately the use of MMF has expanded to include treatment of multiple rheumatic diseases such as systemic sclerosis, systemic lupus erythematosus, inflammatory myopathies and vasculitides. Although we see the use of MMF by rheumatologists within systemic inflammatory diseases, indication lists of MMF remains unchanged. Based on this information, following study is made with the purpose to evaluate the effect of MMF in rheumatic diseases and confirm the validity of its use to these indications. Data was gathered on patients based in the PSKUS due to diagnosis M.32 (SLE) and M.34 (SSc) in the time span 1/1-2021 until 31/12-2021. Variables included age, medical treatment, disease activity score, gender, and use of glucocorticoids. The results show a satisfactory effect of MMF within these diagnoses, where disease activity score can be kept within proposed target ranges
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
Mikofenolāta mofetils, Sistēmiskā sarkanā vilkēde, Sistēmiskā skleroze, Sistēmiskās
saistaudu slimības, Reimatoloģija, Internās slimības, Imūnsupresants, Mycophenolate mofetil, Systemic lupus erythematosus, Systemic sclerosis, Systemic
connective tissue diseases, Rheumatology, Internal medicine, Immunosuppressant.